Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,750,670
  • Shares Outstanding, K 38,873
  • Annual Sales, $ 26,690 K
  • Annual Income, $ -37,840 K
  • 60-Month Beta -0.16
  • Price/Sales 36,595.50
  • Price/Cash Flow N/A
  • Price/Book 38.46
Trade EIDX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.65
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/24/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.74
  • Low Estimate -0.81
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -50.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
116.24 +5.14%
on 01/05/21
132.54 -7.79%
on 01/04/21
-5.49 (-4.30%)
since 12/24/20
3-Month
69.38 +76.16%
on 10/30/20
132.54 -7.79%
on 01/04/21
+48.92 (+66.75%)
since 10/23/20
52-Week
28.39 +330.47%
on 03/16/20
132.54 -7.79%
on 01/04/21
+68.05 (+125.65%)
since 01/24/20

Most Recent Stories

More News
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

-Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval...

BBIO : 70.68 (+8.52%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. ("Eidos") (formerly Nasdaq: EIDX)...

BBIO : 70.68 (+8.52%)
EIDX : 122.21 (-4.85%)
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.

BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) and Eidos Therapeutics, Inc. ("Eidos") (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals...

BBIO : 70.68 (+8.52%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger

BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) and Eidos Therapeutics, Inc. ("Eidos") (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or...

BBIO : 70.68 (+8.52%)
EIDX : 122.21 (-4.85%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds EIDX, IPHI, ALXN, and XLNX Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

EIDX : 122.21 (-4.85%)
IPHI : 164.59 (+3.07%)
ALXN : 152.75 (-0.59%)
XLNX : 130.30 (+3.69%)
ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

ALXN : 152.75 (-0.59%)
SPWH : 16.94 (-1.91%)
CBMG : 19.75 (unch)
STND : 32.67 (-0.03%)
EIDX : 122.21 (-4.85%)
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their...

EIDX : 122.21 (-4.85%)
BBIO : 70.68 (+8.52%)
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote "FOR" Proposed Merger

BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services ("ISS") recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq:...

BBIO : 70.68 (+8.52%)
EIDX : 122.21 (-4.85%)
Lifshitz Law Firm, P.C. Announces Investigation of EIDX, NAV, STND, and WTRE

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Lifshitz Law Firm, P.C.:

EIDX : 122.21 (-4.85%)
NAV : 44.06 (-0.14%)
STND : 32.67 (-0.03%)
WTRE : 34.63 (-0.09%)
WeissLaw LLP Reminds MTSC, EIDX, IPHI, and ALXN Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

MTSC : 58.36 (-0.34%)
EIDX : 122.21 (-4.85%)
IPHI : 164.59 (+3.07%)
ALXN : 152.75 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

See More

Key Turning Points

3rd Resistance Point 139.85
2nd Resistance Point 134.17
1st Resistance Point 128.19
Last Price 122.21
1st Support Level 116.53
2nd Support Level 110.85
3rd Support Level 104.87

See More

52-Week High 132.54
Last Price 122.21
Fibonacci 61.8% 92.75
Fibonacci 50% 80.46
Fibonacci 38.2% 68.18
52-Week Low 28.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar